Intralipid 10% Generic Name & Formulations
Mechanism of Action
Intralipid is metabolized and utilized as a source of energy causing an increase in heat production, decrease in respiratory quotient and increase in oxygen consumption. Intralipid will prevent the biochemical lesions of essential fatty acid deficiency (EFAD), and correct the clinical manifestations of the EFAD syndrome.
Intralipid 10% Indications
To provide a source of calories and essential fatty acids for patients requiring parenteral nutrition. To provide a source of essential fatty acids for prevention of essential fatty acid deficiency (EFAD).
Intralipid 10% Dosage and Administration
Administer by IV infusion via a peripheral or central vein. Initiate rate at 1mL/min for the first 15–30mins; if tolerated, may increase to 2mL/min. Do not infuse >500mL on first day; if tolerated, may increase dose the next day; max: 25mL/kg/day. EFAD: supply 8–10% of caloric input with Intralipid 10%. For complete parenteral nutrition: supplement with amino acids, carbohydrates, electrolytes, multivitamins and trace elements.
Administer by IV infusion via a peripheral or central vein. Premature infants: initially 5mL/kg/day; may increase based on ability to eliminate fat; max: 30mL/kg/day. Older children: initiate rate at max 0.1mL/min for the first 10–15mins; if tolerated, may increase to 1mL/kg/hr. Max dose: 30mL/kg/day. EFAD: supply 8–10% of caloric input with Intralipid 10%. For complete parenteral nutrition: supplement with amino acids, carbohydrates, electrolytes, multivitamins and trace elements.
Intralipid 10% Contraindications
Known hypersensitivity to egg, soybean, or peanut. Severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride >1000mg/dL).
Intralipid 10% Boxed Warnings
Intralipid 10% Warnings/Precautions
Risk of clinical decompensation with rapid infusion of IV lipid emulsion in neonates and infants: monitor closely the infant’s ability to eliminate the infused lipids from circulation (eg, measure serum triglycerides and/or plasma free fatty acid levels. Discontinue infusion if signs or poor clearance of lipids from circulation occur. Risk of parenteral nutrition-associated liver disease (eg, cholestasis or hepatic steatosis), other hepatobiliary disorders (eg, cholecystitis and cholelithiasis); monitor liver function and consider discontinuation or dose reduction if abnormalities occur. Correct severe fluid and electrolyte disorders prior to initiation. Measure serum triglycerides prior to initiation, with each dose increase, and regularly during therapy. Discontinue if hypersensitivity reactions or fat overload syndrome occur. Monitor for signs/symptoms of infection. Refeeding syndrome: monitor closely in severely malnourished and slowly increase nutrient intake. Patients with pulmonary edema, heart failure: monitor fluid status closely. Elderly. Pregnancy. Nursing mothers.
Intralipid 10% Pharmacokinetics
Intralipid 10% Interactions
Vitamin K content may antagonize anticoagulants (eg, coumarin, warfarin); monitor.
Intralipid 10% Adverse Reactions
Intralipid 10% Clinical Trials
Intralipid 10% Note
Intralipid 10% Patient Counseling